department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

HERON THERAPEUTICS, INC. /DE/ ($HRTX) · pharmadog

PUBLIC COMPANY

$HRTXHERON THERAPEUTICS, INC. /DE/

San Diego, CA, USupdated 1h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

2

approvals ytd

1

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Unknown

1 INDICATIONS AND USAGE SUSTOL is indicated in combinatio…

5-hydroxytryptamine receptor 3A

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view HERON THERAPEUTICS, INC. /DE/ jobs →

News

no news has mentioned this company yet

identifiers

ticker

$HRTX

SEC CIK

0000818033

country

US

source

sec_tickers

mentioned in

0news items

entity-linker matched

HERON THERAPEUTICS, INC. /DE/ earnings

HERON THERAPEUTICS, INC. /DE/

Active trials

phase2Pilot Herniorrhaphy Study for Postoperative Analgesiacompletedn=463
phase2Phase 2B Upper Extremity Nerve Block Studycompletedn=243
phase3Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)completedn=418
phase3APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancercompletedn=1,428
phase2Total Knee Arthroplasty Infiltration Study for Postoperative Analgesiacompletedn=285
phase2Phase 2 Herniorrhaphy Study for Opioid Eliminationcompletedn=63
phase3A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HECcompletedn=942
phase3Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimencompletedn=116

more trials →

$HRTX0.4339-1.03%

Insider activity

source: SEC Form 4

routine RSU / option mechanics (6)

Apr 19, 26option exerciseForbes William P · EVP, Chief Development Officer3,874 sh
Apr 19, 26option exerciseForbes William P · EVP, Chief Development Officer3,874 sh
Apr 19, 26option exerciseCollard Craig A · Chief Executive Officer13,797 sh
Apr 19, 26option exerciseCollard Craig A · Chief Executive Officer13,797 sh
Apr 19, 26option exerciseDuarte Ira · EVP, Chief Financial Officer3,874 sh
Apr 19, 26option exerciseDuarte Ira · EVP, Chief Financial Officer3,874 sh

Data sources

SEC EDGAR · openFDA

last refreshed 31m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$HRTX0.4339-1.03%